162 related articles for article (PubMed ID: 23315305)
1. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.
Bloomgarden ZT; Blonde L; Garber AJ; Wysham CH
Endocr Pract; 2012; 18 Suppl 3():6-26; quiz 27-8. PubMed ID: 23315305
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
5. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
6. Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
Kalra S
J Pak Med Assoc; 2014 Mar; 64(3):359-61. PubMed ID: 24864619
[TBL] [Abstract][Full Text] [Related]
7. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
George C; Byun A; Howard-Thompson A
Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
Drab SR
Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
[TBL] [Abstract][Full Text] [Related]
9. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
Ross SA; Ballantine J
Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
[TBL] [Abstract][Full Text] [Related]
11. Recent updates on GLP-1 agonists: Current advancements & challenges.
Sharma D; Verma S; Vaidya S; Kalia K; Tiwari V
Biomed Pharmacother; 2018 Dec; 108():952-962. PubMed ID: 30372907
[TBL] [Abstract][Full Text] [Related]
12. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
13. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
Hanefeld M; Raccah D; Monnier L
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
[TBL] [Abstract][Full Text] [Related]
14. GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL; Garber A
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
[TBL] [Abstract][Full Text] [Related]
15. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
16. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
Porcellati F; Lucidi P; Bolli GB; Fanelli CG
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
[TBL] [Abstract][Full Text] [Related]
18. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
